Hainan Haiyao Co., Ltd. (000566.SZ)
- Previous Close
6.08 - Open
5.43 - Bid 5.90 x --
- Ask 5.91 x --
- Day's Range
5.79 - 6.17 - 52 Week Range
2.83 - 7.11 - Volume
94,869,641 - Avg. Volume
49,345,018 - Market Cap (intraday)
7.603B - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-1.22 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 15, 2018
- 1y Target Est
--
Hainan Haiyao Co., Ltd. manufactures and sells pharmaceutical products and medical devices in China and internationally. The company develops intermediates, APIs, innovative chemical drugs, modern Chinese medicines, biological drugs, cellular immunity products, and high-end medical devices. It offers its products in various forms, such as pills, tablet granules, tincture fluid extracts, powders, syrups, soft capsule raw materials, powder injections, and health foods in various antibiotic series, gastrointestinal medication series, anti-tumor medicine series, cochlear implant series, etc.; and vitamin C for injection scurvy, idiopathic methemoglobinemia, etc. The company also provides internet medical treatment and medical services. Hainan Haiyao Co., Ltd. was founded in 1965 and is headquartered in Haikou, China.
www.haiyao.com.cn2,003
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000566.SZ
View MorePerformance Overview: 000566.SZ
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000566.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000566.SZ
View MoreValuation Measures
Market Cap
7.60B
Enterprise Value
10.33B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.11
Price/Book (mrq)
16.64
Enterprise Value/Revenue
12.38
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-189.11%
Return on Assets (ttm)
-6.31%
Return on Equity (ttm)
-122.46%
Revenue (ttm)
834.28M
Net Income Avi to Common (ttm)
-1.58B
Diluted EPS (ttm)
-1.22
Balance Sheet and Cash Flow
Total Cash (mrq)
495.79M
Total Debt/Equity (mrq)
666.44%
Levered Free Cash Flow (ttm)
1.64B